Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells
Many of the most challenging medical problems facing us today, such as dementia and other neurodegenerative conditions, cancer and various genetic diseases, are caused by faulty molecular pathways that lead to cellular disruption and death.
We are searching for novel therapies that suppress or over-ride these harmful pathways and keep cells healthy. It’s a concept known as synthetic viability.
It may seem counter-intuitive, but our research has shown that combining two biological changes – one causing the disease and the other induced by a treatment – can re-establish normality within cells to ensure their health and proper functioning.
It’s the principle of two wrongs making a right, restoring the balance of life
Based on these ideas, we’re using precision genetic models to search for new applications for existing drugs, novel drug compounds, precision diagnostics and innovative therapeutic targets.
We are also combining our knowledge of the molecular ‘fingerprints’ of sickness and health with computational tools to match detailed disease profiles to therapeutic approaches that are most likely to work.
Building on our successes based on genetic diseases caused by defective DNA repair, we will soon be expanding our research to include a range of other conditions caused by cell dysfunction.
Founders and investors
Adrestia Therapeutics is a joint venture between Professor Steve Jackson, his colleagues and Ahren Innovation Capital.
Professor Steve Jackson, FRS FMedSci
Ahren Innovation Capital
For current job and partnering opportunities please use to the link below.